Logo
W

Wheeler Bio, Inc.

60 employees

Wheeler Bio is a pioneering Contract Development and Manufacturing Organization (CDMO) focused on accelerating the discovery-to-development process for biopharmaceutical companies. Through a unique partnering model, we aim to address industry bottlenecks by facilitating smoother transitions between discovery and development phases, empowering innovators to bring novel antibody and antibody-like therapeutics to market with precision, speed, and optimized cost without ever compromising quality. Wheeler Bio specializes in mammalian cell line and process development, GLP Tox material supply, and CGMP clinical supply, leveraging our Portable CMC® platform to streamline the pathway from innovation to clinical trials. Our approach has been purposefully designed to reduce lifecycle challenges, enhance efficiency, and foster lasting collaborations within the biopharma industry.

Investor insights

Funding rounds participated in

$31M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology

Sectors

Biotechnology

Date founded

2020

Funding rounds raised

Total raised

$31M

from 3 investors over 1 rounds

W

Wheeler Bio, Inc. raised $31M on November 4, 2022

Investors: Charles River Laboratories International, Echo Investment Capital and + 5 Other investors

FAQ